Table 3:
The follow-up data
| Parameters | Conventional group | Perceval group | P-value |
|---|---|---|---|
| Lost to follow-up (n) | 3 (2.9%) | 3 (6.1%) | |
| Mean follow-up time (months) | 32.7 ± 15.5 | 22.7 ± 17.5 | 0.002 |
| Mean gradient (mmHg) | 15.4 ± 6.3 | 13.6 ± 5.4 | n.s. |
| EOA (cm2) | 1.3 ± 0.2 | 1.5 ± 0.25 | <0.001 |
| Mortality at 1 year (n) | 10 (16.4%) | 5 (13.2%) | n.s. |
| Cause (cardiac, pulmonary, renal, Ca, unknown) | (4/1/2/1/2) | (1/2/1/1/0) | |
| Mortality at 3 years (n) | 12 (34.3%) | 9 (39.1%) | n.s. |
| Cause (cardiac, pulmonary, renal, Ca, sepsis, unknown) | 4/1/2/1/1/3 | 1/2/1/1/1/1/3 | |
| Endocarditis (n) | 1 (1.4%) | 3 (6%) | n.s. |
| Re-AVR (n) | 1 (1.4%) | 2 (4%) | n.s. |
EOA: effective orifice area; Re-AVR: Re-aortic valve replacement.